Suzhou Zelgen Biopharmaceuticals Co., Ltd. (688266.SS)
CNY 108.11
(4.87%)
CNY 108.11
(4.87%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -278.58 Million CNY | 42.67% |
| 2022 | -485.94 Million CNY | -5.19% |
| 2021 | -461.99 Million CNY | -48.71% |
| 2020 | -310.67 Million CNY | 30.65% |
| 2019 | -447.98 Million CNY | -1.79% |
| 2018 | -440.08 Million CNY | -200.47% |
| 2017 | -146.46 Million CNY | -14.19% |
| 2016 | -128.26 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -39.49 Million CNY | 48.36% |
| 2024 Q2 | -27.03 Million CNY | 31.55% |
| 2024 Q3 | -31.36 Million CNY | -16.02% |
| 2023 Q4 | -76.49 Million CNY | 12.94% |
| 2023 FY | -278.58 Million CNY | 42.67% |
| 2023 Q3 | -87.86 Million CNY | -54.14% |
| 2023 Q2 | -57 Million CNY | 4.8% |
| 2023 Q1 | -59.87 Million CNY | 39.29% |
| 2022 FY | -485.94 Million CNY | -5.19% |
| 2022 Q3 | -124.35 Million CNY | 8.71% |
| 2022 Q2 | -136.22 Million CNY | -7.47% |
| 2022 Q1 | -126.74 Million CNY | 19.94% |
| 2022 Q4 | -98.62 Million CNY | 20.69% |
| 2021 Q2 | -97.25 Million CNY | -22.01% |
| 2021 Q1 | -79.71 Million CNY | 12.27% |
| 2021 FY | -461.99 Million CNY | -48.71% |
| 2021 Q4 | -158.32 Million CNY | -36.84% |
| 2021 Q3 | -115.7 Million CNY | -18.97% |
| 2020 Q4 | -90.85 Million CNY | 8.92% |
| 2020 Q3 | -99.75 Million CNY | -50.35% |
| 2020 Q1 | -62.26 Million CNY | 1.93% |
| 2020 FY | -310.67 Million CNY | 30.65% |
| 2020 Q2 | -66.35 Million CNY | -6.57% |
| 2019 FY | -447.98 Million CNY | -1.79% |
| 2019 Q4 | -63.48 Million CNY | -10.9% |
| 2019 Q3 | -57.24 Million CNY | 66.53% |
| 2019 Q2 | -171.01 Million CNY | -0.52% |
| 2019 Q1 | -170.13 Million CNY | 51.17% |
| 2018 Q4 | -348.44 Million CNY | 0.0% |
| 2018 FY | -440.08 Million CNY | -200.47% |
| 2017 FY | -146.46 Million CNY | -14.19% |
| 2016 FY | -128.26 Million CNY | 0.0% |